SkylineDx
SkylineDx is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Sponsor Bioinvent International AB
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The trial was conducted at 12 centers in Europe and the United States, of which 8 centers enrolled participants.
- Forty-two participants were screened by 9 sites, and 35 participants were enrolled over approximately 16 months.
- The planned Phase 2a part was not initiated.
These findings describe the trial, not the service provider’s performance or responsibility.
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Sponsor BioInvent International AB
- Start (EU)
- Latest update
- Estimated end
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies
Sponsor BioInvent International AB
- Start (EU)
- Latest update
- Estimated end
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
Sponsor BioInvent International AB
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma
Sponsor BioInvent International AB
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for SkylineDx?
The 2026-10-09 snapshot links SkylineDx to 5 distinct CTIS trials. Recorded services include Laboratory services, mRNA expression from Tumour biopsies (Biomarker/exploratory), tumor tissue analysis, Tumor tissue analysis (mRNA), among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for SkylineDx?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Dermatology, Gastroenterology, Gynecology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to SkylineDx conducted?
The linked trials record locations in 8 countries, including Spain, Germany, Poland, Sweden, Denmark. These are trial locations, not confirmed office locations or countries where SkylineDx delivered services.
What can this page tell me about SkylineDx's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under SkylineDx. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- SkylineDx B.V.